Covid-19: Handling of Marketing Authorisations

Recommendation
14/15 October 2025
With updates on the CEP 2.0!
The processes and procedures relating to marketing authorisations are still strongly influenced by the corona pandemic. On the website of the HMA (Heads of Medicines Agencies) this has been reiterated and the available templates and information to facilitate and manage marketing authorisations and registration procedures have been consolidated and listed.
In addition to the continuously updated catalogue"QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC", the "Template for submission of an application for a Covid-19 exeptional change management process (ECMP)" and the "Template for Step 3 Notification of implementation" are available here.
The overview of the information provided and application templates can be found on the website of the HMA (Heads of Medicines Agencies) in the section CMDh.
Related GMP News
01.10.2025Updated Classification Guideline Published
16.09.2025EMA updates IRIS Documents
16.09.2025eSubmission: Update to the 'PLM Portal eAF - Release Notes'
16.09.2025Centralised Procedures: Updated Q&As
06.08.2025WHO: TRS 1060 regulatory Guidelines published
30.07.2025Swissmedic/EMA: M4Q(R2) Guideline published for Comment